Background: Autism spectrum disorder (ASD) is a neurobiological disorder characterized by distinctive impairments in cognitive function, language, and behavior. Linkage and population studies suggest a genetic association between solute carrier family 6 member 4 (SLC6A4) variants and ASD. Method: Logistic regression was used to identify associations between single-nucleotide polymorphisms (SNPs) and ASD with 3 alternative models (additive, dominant, and recessive). Linear regression analysis was performed to determine the influence of SNPs on Childhood Autism Rating Scale (CARS) scores as a quantitative phenotype. Results: In the present study, we examined the associations of SNPs in the SLC6A4 gene and the fibrinogen alpha chain (FGA) gene. Logistic regression analysis showed a significant association between the risk of ASD and rs2070025 and rs2070011 in the FGA gene. The gene-gene interaction between SLC6A4 and FGA was not significantly associated with ASD susceptibility. However, polymorphisms in both SLC6A4 and the FGA gene significantly affected the symptoms of ASD. Conclusion: Our findings indicate that FGA and SLC6A4 gene interactions may contribute to the phenotypes of ASD rather than the incidence of ASD.

Keywords:
Autism spectrum disorder, Polymorphism, Childhood Autism Rating Scale, SLC6A4, FGA
1.
Costa e Silva JA: Autism, a brain developmental disorder: some new pathopysiologic and genetics findings. Metabolism 2008;57(suppl 2):S40-S43.
2.
Faras H, Al Ateeqi N, Tidmarsh L: Autism spectrum disorders. Ann Saudi Med 2010;30:295-300.
3.
Folstein S, Rutter M: Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977;18:297-321.
4.
Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M: Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25:63-77.
5.
Taniai H, Nishiyama T, Miyachi T, Imaeda M, Sumi S: Genetic influences on the broad spectrum of autism: study of proband-ascertained twins. Am J Med Genet B Neuropsychiatr Genet 2008;147B:844-849.
6.
Anney R, Klei L, Pinto D, et al: Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet 2012;21:4781-4792.
7.
Weiss LA, Arking DE, Daly MJ, Chakravarti A: A genome-wide linkage and association scan reveals novel loci for autism. Nature 2009;461:802-808.
8.
Casey JP, Magalhaes T, Conroy JM, et al: A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet 2012;131:565-579.
9.
Ben-David E, Shifman S: Networks of neuronal genes affected by common and rare variants in autism spectrum disorders. PLoS Genet 2012;8:e1002556.
10.
Sodhi MS, Sanders-Bush E: Serotonin and brain development. Int Rev Neurobiol 2004;59:111-174.
11.
Gingrich JA, Hen R: Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 2001;155:1-10.
12.
Anderson GM: Genetics of childhood disorders: XlV - autism. 4. Serotonin in autism. J Am Acad Child Adolesc Psychiatry 2002;41:1513-1516.
13.
Zafeiriou DI, Ververi A, Vargiami E: The serotonergic system: its role in pathogenesis and early developmental treatment of autism. Curr Neuropharmacol 2009;7:150-157.
14.
Whitaker-Azmitia PM: Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? Int J Dev Neurosci 2005;23:75-83.
15.
McCauley JL, Olson LM, Dowd M, Amin T, Steele A, Blakely RD, Folstein SE, Haines JL, Sutcliffe JS: Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am J Med Genet B Neuropsychiatr Genet 2004;127B:104-112.
16.
Cook EH Jr, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, Haas R, Courchesne E, Leventhal BL: Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997;2:247-250.
17.
Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C, Folstein SE, Blakely RD: Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 2005;77:265-279.
18.
Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN: Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2003;2:365-380.
19.
Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR, Bento C, Marques C, Ataide A, Miguel T, Borges L, Vicente AM: Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol Psychiatry 2004;9:264-271.
20.
Cho IH, Yoo HJ, Park M, Lee YS, Kim SA: Family-based association study of 5-HTTLPR and the 5-HT2A receptor gene polymorphisms with autism spectrum disorder in Korean trios. Brain Res 2007;1139:34-41.
21.
Carneiro AM, Cook EH, Murphy DL, Blakely RD: Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008;118:1544-1552.
22.
Rivas G, Tangemann K, Minton AP, Engel J: Binding of fibrinogen to platelet integrin alpha IIb beta 3 in solution as monitored by tracer sedimentation equilibrium. J Mol Recognit 1996;9:31-38.
23.
Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa V, Sunyer J, Bellander T, Chalamandaris AG, Pistelli R, Koenig W, Peters A: Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008;52:941-952.
24.
Wu S, Guo Y, Jia M, Ruan Y, Shuang M, Liu J, Gong X, Zhang Y, Yang J, Yang X, Zhang D: Lack of evidence for association between the serotonin transporter gene (SLC6A4) polymorphisms and autism in the Chinese trios. Neurosci Lett 2005;381:1-5.
25.
Seneviratne C, Huang W, Ait-Daoud N, Li MD, Johnson BA: Characterization of a functional polymorphism in the 3′ UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin Exp Res 2009;33:332-339.
26.
Wray NR, James MR, Gordon SD, Dumenil T, Ryan L, Coventry WL, Statham DJ, Pergadia ML, Madden PA, Heath AC, Montgomery GW, Martin NG: Accurate, large-scale genotyping of 5 HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety, and personality measures. Biol Psychiatry 2009;66:468-476.
27.
Folstein SE, Rosen-Sheidley B: Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001;2:943-955.
28.
Mulder EJ, Anderson GM, Kema IP, de Bildt A, van Lang ND, den Boer JA, Minderaa RB: Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry 2004;43:491-499.
29.
Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, Cohen J, Mannangatti P, Jessen T, Thompson BJ, Ye R, Kerr TM, Carneiro AM, Crawley JN, Sanders-Bush E, McMahon DG, Ramamoorthy S, Daws LC, Sutcliffe JS, Blakely RD: Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci USA 2012;109:5469-5474.
30.
Yoo HJ, Cho IH, Park M, Yang SY, Kim SA: No association study of SLC6A4 polymorphisms with Korean autism spectrum disorder. Korean J Biol Psychiatry 2009;16:121-126.
31.
Su S, Zhao J, Bremner JD, Miller AH, Tang W, Bouzyk M, Snieder H, Novik O, Afzal N, Goldberg J, Vaccarino V: Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet 2009;2:614-620.
32.
Mannila MN, Eriksson P, Leander K, Wiman B, de Faire U, Hamsten A, Silveira A: The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6 concentration. J Int Med 2007;261:138-147.
33.
Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Juhasz G, Bagdy G: New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 2008;64:498-504.
34.
Weiss LA, Ober C, Cook EH Jr: ITGB3 shows genetic and expression interaction with SLC6A4. Hum Genet 2006;120:93-100.
35.
Coutinho AM, Sousa I, Martins M, Correia C, Morgadinho T, Bento C, Marques C, Ataide A, Miguel TS, Moore JH, Oliveira G, Vicente AM: Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet 2007;121:243-256.
36.
Ellis SJ, Tanentzapf G: Integrin-mediated adhesion and stem-cell-niche interactions. Cell Tissue Res 2010;339:121-130.
37.
Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, Fowkes FG: Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc 2007;55:700-707.
38.
Marioni RE, Deary IJ, Murray GD, Lowe GD, Strachan MW, Luciano M, Houlihan LM, Gow AJ, Harris SE, Rumley A, Stewart MC, Fowkes FG, Price JF: Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts. Behav Genet 2011;41:691-699.
39.
Cohen J: Statistical Power Analysis for the Behavioral Sciencies, ed 2. Hillsdale, Erlbaum, 1988.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.